Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
12/2007
12/04/2007US7304059 Substituted quinazolin-4-ylamine analogues
12/04/2007US7304058 For therapy of Alzheimer's disease, depression
12/04/2007US7304056 N-(3-tetrahydrobenzodiazepinonyl)succamides: 2R,3S)N1-[1,3,4,5-tetrahydro-1-(3-phenoxybenzyl)-2-oxo-5-(phenyl)-2H-1,5-benzodiazepin-3-yl]-2-(2-methylpropyl)-3-(propyl)-butanediamide; inhibit production of A beta -peptide, preventing neurological amyloid deposits; Alzheimer's disease
12/04/2007US7304055 Succinoylamino lactams as inhibitors of Aβ protein production
12/04/2007US7304051 Quinoxaline compounds
12/04/2007US7304049 Succinamides N-monosubstituted with with a dibenzo[b,e]azepinone group that inhibit the production of A beta-peptide, acting to prevent the formation of neurological deposits of amyloid protein; treating Alzheimer's Disease
12/04/2007US7304047 Method of treating substance abuse with quetiapine
12/04/2007US7304033 Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
12/04/2007US7304031 Methods and means for producing proteins with predetermined post-translational modifications
12/04/2007US7304029 Inducing a neuroprotective effect of rescuing neurons destined to degenerate or die as a result of hypoxia or ischemia in a brain of a patient by administering growth hormone centrally to the brain of the patient
12/04/2007US7303895 Choline transport like (CTL) membrane proteins involved in choline transport
12/04/2007US7303889 Ligand for G-protein coupled receptor GPR43 and uses thereof
12/04/2007US7303885 For treating or detecting MIF (macrophage migration inhibitor factor) related diseases by detecting MIF/Jab1 (c-Jun activation domain binding protein) interactions; complex MIF in natural association with Jab1 and optionally another protein
12/04/2007CA2345622C Tricyclic .delta.3-piperidines as .alpha.2-antagonists
12/04/2007CA2276170C Sustained analgesia achieved with buprenorphine
12/04/2007CA2239313C Solid compound, its preparation and use in medicine
12/04/2007CA2233315C Pharmaceutical compositions containing hydroximic acid derivatives
12/04/2007CA2227039C One pot synthesis of 2-oxazolidinone derivatives
12/04/2007CA2212205C Use of xanthine derivatives for the modulation of apoptosis
11/2007
11/29/2007WO2007137167A2 Co-therapy for the treatment of epilepsy
11/29/2007WO2007137164A2 Co-therapy for the treatment of epilepsy and related disorders
11/29/2007WO2007137029A1 Therapeutic fluoroethyl ureas
11/29/2007WO2007136743A2 Dothiepin and methods of using the same to treat sleep disorders
11/29/2007WO2007136741A2 N-desmethyl-doxepin and methods of using the same to treat sleep disorders
11/29/2007WO2007136156A1 Methods and compositions for treating motor neuron diseases comprising mesenchymal stem cells
11/29/2007WO2007136042A1 Ameliorating agent for brain damage
11/29/2007WO2007135970A1 Heterocyclic type cinnamide derivative
11/29/2007WO2007135969A1 Urea type cinnamide derivative
11/29/2007WO2007135505A2 Veterinary pharmaceutical compositions for the treatment of pain and inflammation
11/29/2007WO2007135406A2 New forms of active pharmaceutical ingredient
11/29/2007WO2007135387A1 Inhibitor of adenylyl cyclase for treating a disorder of the circadian rhythm
11/29/2007WO2007135294A2 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same
11/29/2007WO2007135242A1 Composition for foodstuff for binding acetaldehyde
11/29/2007WO2007135220A1 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
11/29/2007WO2007135195A1 Ectonucleotidase inhibitors
11/29/2007WO2007135193A2 Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
11/29/2007WO2007135131A1 Substituted pyrazinone derivatives for use as a medicine
11/29/2007WO2007135122A1 Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
11/29/2007WO2007135121A1 Novel 8,10-diaza-bicyclo[4.3.1]decane derivatives and their medical use
11/29/2007WO2007135120A1 Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use
11/29/2007WO2007135027A1 Substituted pteridines substituted with a four-membered heterocycle
11/29/2007WO2007134868A2 3,5-dihydroxy-2,4-cyclohexadienones and their derivatives, dietary compositions and fortified food containing them and their uses
11/29/2007WO2007134362A1 2-ARYLPYRAZOLO[L,5-α]PYRIMIDIN-3-YL ACETAMIDE DERIVATIVES AS LIGANDS FOR TRANSLOCATOR PROTEIN (18 KDA)
11/29/2007WO2007120599A3 Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
11/29/2007WO2007113172A3 Antibodies against amyloid-beta peptide
11/29/2007WO2007110047A3 TERGURIDE/PROTERGURIDE FOR THE TREATMENT OF CHRONIC PAIN (e.g. MIGRAINE)
11/29/2007WO2007106537A3 Aminoquinolones as gsk-3 inhibitors
11/29/2007WO2007104780A3 N- carbamoylmethyl- 4- (r) -phenyl-2-pyrr0lidin0ne, method of its preparation and pharmaceutical use
11/29/2007WO2007100366A3 Quinolone m1 receptor positive allosteric modulators
11/29/2007WO2007099162A3 Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents
11/29/2007WO2007098964A3 Pyrrazole derivatives as sigma receptors antagonists
11/29/2007WO2007075895A3 Heterocyclic derivatives as modulators of ion channels
11/29/2007WO2007074346A3 Modulation of wnt signalling pathways for treating nervous system disorders
11/29/2007WO2007073888A3 Pharmaceutical composition containing donepezil hydrochloride, tablets produced therefrom and method for producing the same
11/29/2007WO2007068750A3 Immunoglobulins directed against nogo
11/29/2007WO2007034465A3 Use of il-1f5 for the modulation of an immune-mediated response
11/29/2007WO2007023389B1 Polymorphic forms of 3-amino-1-propanesulfonic acid
11/29/2007US20070276039 Pharmaceutical uses for alpha2delta ligands
11/29/2007US20070276035 Treatment of neurotic disorders
11/29/2007US20070276025 Indirubin-Type Compounds, Compositions, and Methods for Their Use
11/29/2007US20070276015 Crystal modification of torasemide
11/29/2007US20070276001 Biphenyl-pyrazolecarboxamide compounds
11/29/2007US20070275990 Heterocyclic Spiro Compound
11/29/2007US20070275984 Novel Thieno-Pyridine and Thieno-Pyrimidine Derivatives and Their Use as Positive Allosteric Modulators of Mglur2-Receptors
11/29/2007US20070275983 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
11/29/2007US20070275979 Novel Compounds
11/29/2007US20070275975 3-quinuclidinyl amino-substituted biaryl derivatives
11/29/2007US20070275973 Aryl fused azapolycyclic compounds
11/29/2007US20070275964 Cannabinoid receptor ligands and uses thereof
11/29/2007US20070275959 Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents
11/29/2007US20070275958 Use of Oxicam Compounds
11/29/2007US20070275948 7-[4-(4-Chlorobenzyloxy)Benzenesulfonyl]-8-Methoxy-3-Methyl-2,3,4,5-Tetrahydro-1h-3-Benzazepinium Maleate Or Tosylate As antipyschotics
11/29/2007US20070275943 Method and Composition for Treatment or Prophylaxis of Amyloidosis Disorders
11/29/2007US20070275926 Treatment of disorders of the peripheral nervous system
11/29/2007US20070275910 Phosphoramidate Derivatives
11/29/2007US20070275908 Methods and Compositions for the Enzymatic Synthesis of Gangliosides
11/29/2007US20070275900 HIV protease inhibitory compounds with ameliorated solubility and/or bioavailability; conjugates of therapeutic compound and a peptide wherein the conjugate is cleavable by dipeptidyl-peptidases
11/29/2007US20070275899 Treatment Of Demyelinating Autoimmune Disease with Modified Ordered Peptides
11/29/2007US20070275887 Method of Inhibiting Secretase Activity
11/29/2007US20070275102 Method of affecting sleep and sleep-related behaviors
11/29/2007US20070275095 Treatment of inflammatory, autoimmune, or other disorders, using agents that reduce the sequestering of zinc by calprotectin
11/29/2007US20070275083 ameliorating chronic renal insufficiency, hypertension, atherosclerosis, and chronic congestive heart failure
11/29/2007US20070275067 Compression Coated Tablet Comprising Sumatriptan
11/29/2007US20070275060 Extended release solid pharmaceutical composition containing carbidopa and levodopa
11/29/2007US20070274979 Compositions and Methods for Promoting Neuronal Outgrowth
11/29/2007US20070274974 Compositions and methods for restoring immune responsiveness in patients with immunological defects
11/29/2007US20070274971 Method of Proliferating Precursor Cells
11/29/2007US20070274969 Immortalization of Mammalian Cells
11/29/2007US20070274966 Neural regeneration with transplanted AC133 positive cells
11/29/2007US20070274962 Methods and Composition for Transplantation of Dopaminergic Neurons for Parkinson's Disease
11/29/2007US20070274961 Composition and Methods for Cell Culturing and Tissue Culture Platforms
11/29/2007US20070274952 Compositions and Methods for Modifying the Content of Polyunsaturated Fatty Acids in Biological Cells
11/29/2007US20070274910 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility
11/29/2007DE202007011042U1 Polymorphe Formen von Flupirtinmaleat Polymorphic forms of flupirtine maleate
11/29/2007DE10259834B4 Test und Screeningverfahren zur Identifizierung von Inhibitoren von Beta-Sekretasen Test and screening methods for identifying inhibitors of beta secretases
11/29/2007CA2653117A1 Substituted pteridines substituted with a four-membered heterocycle
11/29/2007CA2653042A1 Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
11/29/2007CA2652983A1 Use of proinsulin for the preparation of a neuroprotective pharmaceutical composition, therapeutic composition containing it and applications thereof
11/29/2007CA2652675A1 Chondroitin sulfate degradation to ameliorate brain damage induced by hypoxia
11/29/2007CA2652537A1 Veterinary pharmaceutical compositions for the treatment of pain and inflammation
1 ... 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 ... 1833